Sign in Subscribe

ANKTIVA Shows Promise in Lung Cancer Treatment

ImmunityBio's (IBRX) ANKTIVA demonstrates improved immune response and survival in non-small cell lung cancer patients when combined with checkpoint inhibitors.

ANKTIVA Shows Promise in Lung Cancer Treatment
Photo by National Cancer Institute on Unsplash
Already have an account? Sign in.